Bioventus Inc. (BVS) Guidance & Earnings Results

On 2026-08-05 Bioventus Inc. reaffirmed guidance: "Reaffirmed revenue, Adjusted Diluted EPS and cash from operations guidance for full year…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

BVSBioventus Inc.Follow BVS — free

Medical Devices · Healthcare

—

Price chart with a free account

Market cap: 1.3B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 10 Nov, in 17 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
5 Aug 26	Reaffirmed	Reaffirmed revenue, Adjusted Diluted EPS and cash from operations guidance for full year 2026 · full year
6 May 26	Raised	Non-GAAP EPS and Cash from Operations guidance raised; revenue guidance reaffirmed · full year
5 Mar 26	Raised	2026 financial guidance reflects continued above-market revenue growth, higher earnings and robust cash generation · full year
4 Nov 25	Reaffirmed	FY2025 net sales guidance $560-$570M, organic growth ~6.1%-8.0% · full year
6 Aug 25	Reaffirmed	FY2025 revenue, Adjusted EBITDA, Non-GAAP EPS guidance reiterated; estimated impact of tariffs included. · full year

Bioventus Inc. — questions

What guidance did Bioventus Inc. give?: On 2026-08-05: "Reaffirmed revenue, Adjusted Diluted EPS and cash from operations guidance for full year 2026"
When does Bioventus Inc. report earnings?: Bioventus Inc.'s next earnings report is expected on 2026-11-10.

Every figure on this page comes from Bioventus Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.